Scientific article: Comparing PD-1 and PD-L1 Mouse Monoclonal Antibodies

by | Mar 4, 2024 | Cancer, Immunology, in vivo Studies, Neurology

ARTICLE FROM BIO X CELL

Comparing PD-1 and PD-L1 mouse monoclonal antibodies

Bio X Cell has recently published a scientific article featuring a journal publication comparing PD-1 and PD-L1 mouse monoclonal antibodies.

Immunotherapy utilizing blockade of the PD-L1/PD-1 pathway has significantly impacted the treatment of cancer. Experimental models play a pivotal role in preclinical research, allowing scientists to answer questions about this important pathway and explore therapeutic combinations.

Read more about the publication summary, get the tip on how to choose an anti-PD-1 antibody for your next research project from Bio X Cell, as well as to explore additional Bio X Cell immune checkpoint antibodies.

ABOUT BIO X CELL

Antibodies For In Vivo Research

Bio X Cell antibodies are formulated for in vivo experiments and used extensively in animal models of human disease. They feature greater than 95% purity, ultra-low endotoxin levels, and are presevative, stabilizer, and carrier protein-free. Bio X Cell has developed a wide range of antibodies for immuno-oncology, immunology, and neuroscience research. Their products are cited in over 15,000 publications that detail a broad range of applications, including in vivo cell-specific depletion, cytokine neutralization, immune checkpoint blockade, and more.

 

    • Exceptional Purity
    • Pathogen Free
    • Ultra-low Endotoxin Level
    • Advanced Binding Validation
    • Low Protein Aggregation
    • Marching Isotype Control Antibodies

All products listed on this site and sold through LAB-A-PORTER Limited are for research use only (RUO). Not for human use. Not for therapeutic or diagnostic use.

Reference: 

  1. Bio X Cell, ‘Comparing PD-1 and PD-L1 Mouse Monoclonal Antibodies’ Available at https://bioxcell.com/comparing-pd-1-and-pd-l1-mouse-monoclonal-antibodies/

Learn more on our comprehensive in-vivo research reagents today.

Contact us
Share This